THE CLINICAL BURDEN OF BLADDER CANCER TO THE BRAZILIAN SOCIETY

Author(s)

Rosim MP1, Sarti FM1, Riveros B2, Lucchetta RC2, Pedro GO3, Scatena D3, Okumura LM4, Nita ME5, Massaoka MH6, Volsi EC6, Matsuo AL6, Guerra RL7, Fay AP8
1University of Sao Paulo, sao paulo, Brazil, 2Federal University of Parana, Curitiba, Brazil, 3MAPES, São Paulo, Brazil, 4Pontifícia Universidade Católica (PUC-RS), Porto Alegre, Brazil, 5USP and FIPE/HAOC, Sao Paulo, Brazil, 6AstraZeneca, Cotia, Brazil, 7National Institute of Cancer, Rio de Janeiro, Brazil, 8PUCRS - School of Medicine, Porto Alegre, Brazil

OBJECTIVES: To estimate the clinical burden of bladder cancer (BC) to the Brazilian society through the calculation of disability-adjusted life years (DALY).

METHODS: DALY was calculated considering the estimated years of life lost (YLL) and years lived with disability (YLD) related to the disease. YLL was calculated based on the life expectancy presented by the Brazilian Institute of Geography and Statistics (IBGE) for each age (Complete Mortality Table for Brazil, 2014) and the mortality data from BC by age group presented (Brazilian Mortality Information System 2014). Age-weighting and a discount rate of 5%, as recommended by the Brazilian Ministry of Health, were used. YLD were calculated by multiplying incidence of BC in 2014 (Brazilian National Institute of Cancer), length of disability and weight of disability, related to disease stages and their respective duration of a conceptual model of BC developed based on literature and specialists’ opinion. Disability weights were based on the Global Burden of Disease Study (2013).

RESULTS: Considering the discount rate and age weighting, in 2014 there was a loss of 27,738 years due to the premature death of patients with bladder cancer, of which 17,701 years corresponded to male patients and 10,037 to female patients. Based on the incidence of 8,940 patients in 2014, the total YLD was of 12,402. Total DALY due to bladder cancer in 2014 was 40,140.

CONCLUSIONS: BC is responsible for a high clinical burden in patients, both due to disability resulting from treatment and from premature mortality. This data can support strategic actions of public health policies aimed at the prevention and early diagnosis of BC, as well as on the decision-making process for choosing preferential treatment.

Conference/Value in Health Info

2017-11, ISPOR Europe 2017, Glasgow, Scotland

Value in Health, Vol. 20, No. 9 (October 2017)

Code

PCN258

Topic

Health Service Delivery & Process of Care

Topic Subcategory

Treatment Patterns and Guidelines

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×